Publications Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab Citation Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1209-1217.e2. doi: 10.1016/j.cgh.2020.04.078. Epub 2020 May 4. PMID: 32376505. Abstract Background & aims: Infliximab is an effective treatment for moderate to severe ulcerative colitis (UC). Little is known about patient-related factors that might be used to predict endoscopic healing with infliximab therapy. Methods: We analyzed data from 484 patients included in the randomized trials of the effects of infliximab therapy for patients with UC (Active Ulcerative Colitis Trials [ACT]-1 and ACT-2). We used a 2-compartment population pharmacokinetic model to calculate baseline infliximab clearance. Two multivariable regression models were derived and validated for their ability to identify patients with endoscopic healing (Mayo endoscopic score, ≤1) at weeks 8 and 30, using only baseline variables. We developed a clinical decision support tool (CDST) and calculator to determine the probability of endoscopic healing in patients starting infliximab. Tags Anti-TNF, Endoscopy, IBD, Inflammatory Bowel Disease, Response to Therapy, Treatment Outcome, Ulcerative Colitis, Wound Healing Read More